Understanding olfactory dysfunction in COVID-19: Expression of ACE2, TMPRSS2 and Furin in the nose and olfactory bulb in human and mice

Short Summary: ACE2, TMPRSS, and Furin expression patterns suggest sensorineural dysfunction without olfactory neuronal damage in COVID-19-associated anosmia.

Rumi Ueha1*, M.D., Ph.D.; Kenji Kondo1 M.D., Ph.D.; Ryoji Kagoya1 M.D., Ph.D.; Shigeyuki Shichino2, Ph.D.; Satoshi Ueha2, Ph.D.; and Tatsuya Yamasoba M.D., Ph.D.

1. Department of Otolaryngology and Head and Neck Surgery, Faculty of Medicine, the University of Tokyo, Tokyo, Japan

2. Division of Molecular Regulation of Inflammatory and Immune Diseases, Research Institute for Biomedical Sciences, Tokyo University of Science, Chiba, Japan

Correspondence to: Rumi Ueha

Department of Otolaryngology and Head and Neck Surgery, Faculty of Medicine, the University of Tokyo, Tokyo, Japan, 113-8655
1 E-mail: ruu1025@yahoo.co.jp

2 Tel: +81-3-3815-5411, Fax: +81-3-3814-9486
Abstract

Background: Anosmia is a frequent symptom in coronavirus disease 2019 (COVID-19) patients that generally resolves within weeks. In contrast, the anosmia caused by other upper respiratory infections affects a small proportion of patients and may take months to resolve or never resolve. The mechanisms behind COVID-19-induced olfactory dysfunction remain unknown. Here, we address the unique pathophysiology of COVID-19-associated olfactory dysfunction.

Methods: The expression of ACE2 (virus binding receptor) and TMPRSS2 and Furin (host cell proteases facilitating virus entry) was examined in the nasal mucosa, composed of respiratory mucosa (RM), olfactory mucosa (OM), and olfactory bulb (OB) of mouse and human tissues using immunohistochemistry and gene analyses.

Results: Co-expression of ACE2, TMPRSS2, and Furin was observed in the RM and in the OM, especially in the supporting cells of the olfactory epithelium and the Bowman’s glands. Notably, the olfactory receptor neurons (ORNs) in the OM were positive for ACE2 but almost negative for TMPRSS2 and Furin. Cells in the OB expressed ACE2 strongly and Furin weakly, and did not express TMPRSS2. All three gene expressions were confirmed in the nasal mucosa and OB.
Conclusions: ACE2 was widely expressed in all tissues, whereas TMPRSS2 and Furin were expressed only in certain types of cells and were absent in the ORNs. These findings, together with clinical reports, suggest that COVID-19-related anosmia occurs mainly through sensorineural and central dysfunction and, to some extent, conductive olfactory dysfunction. The expression of ACE2, but not TMPRSS2 or Furin, in ORNs may explain the early recovery from anosmia.
Introduction

The recent international spread of the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a serious health emergency. COVID-19 usually begins with simple respiratory symptoms such as fever, sore throat, and cough for 2–3 days (1, 2). Notably, chemosensitive disorders, such as loss or decline of smell (anosmia or hyposmia), and loss of taste (ageusia or dysgeusia), have been repeatedly reported as unique clinical features of COVID-19 (3, 4), and are now considered typical symptoms of the early stages of SARS-CoV-2 infection (4, 5). A recent published meta-analysis demonstrated a 52.73% prevalence of olfactory dysfunction among 1,627 COVID-19 patients (6). Specifically, a high rate of anosmia (complete loss of smell) is well documented (3, 5, 7, 8).

In contrast, only a small proportion (up to 20%) of patients with upper respiratory infection (URI) exhibits olfactory dysfunction (9). The prognosis of olfactory dysfunction due to URI is generally poor, with the majority of patients showing no or slight recovery within a few months (10), whereas olfactory dysfunction in COVID-19 patients resolves relatively rapidly, with a reported duration of 1 to 4 weeks (3, 8, 11-13). In a cohort study of COVID-19 patients with olfactory dysfunction, loss of smell was reported to be the first symptom in 27% of patients (12). Thus, the clinical features of COVID-19-associated olfactory dysfunction are significantly different from
those found in patients with common URIs, which are caused by viruses such as rhinovirus, picornavirus, and parainfluenza virus (9, 14-16).

SARS-CoV-2 host cell entry depends on several factors: the binding of viral spike proteins to the cellular receptor angiotensin-converting enzyme 2 (ACE2) (17-19), spike protein cleavage by the host cell enzyme Furin (19-21), and spike protein priming by host cell proteases such as transmembrane protease serine 2 (TMPRSS2) (19, 22). Thus, the high expression of ACE2, TMPRSS2, and Furin is thought to enhance SARS-CoV-2 entry as well as clinical symptoms.

Based on its histological components and functions, the nasal mucosa is divided into the respiratory mucosa (RM) and the olfactory mucosa (OM). The RM consists of various types of epithelial cells, including ciliated columnar and goblet cells. The OM serves olfaction and consists of the olfactory epithelium (OE) and subepithelial tissues (23). The degree of olfaction is closely related to the number of mature olfactory receptor neurons (ORNs) in the OE. The olfactory system consists of peripheral compartments such as the OM, and central structures such as the olfactory bulb (OB) and the piriform/entorhinal cortex (24).

To date, the expression of ACE2 (25, 26) and TMPRSS2 (26), but not Furin, has been reported in the nasal epithelium. However, the histological evaluation of their expression has
been limited; only one study reported the expression of ACE2 and TMPRSS2 proteins in the nasal mucosa and respiratory sinus, although it did not demonstrate immunostaining images of the nasal mucosa (27). In the present study, we sought to elucidate the mechanisms underlying olfactory dysfunction and the pathogenesis of high viral load in the upper airways of COVID-19 patients. Toward that aim, we investigated the expression of ACE2, TMPRSS2, and Furin in the RM, OM, and OB of human and mouse tissues.

Methods

Experimental samples

Animal tissue samples were all obtained from the mice examined in the previous published studies (23, 28), because purchasing new animals had been prohibited in our facility due to the epidemic spread. The samples from 6 eight-week-old male C57BL/6 mice (23) and an eight-week-old- male Sprague Dawley rat (28) were used, and the following paraffin-embedded tissues were collected; the RM area and OM area of the nose, the OB area, and the kidney and prostate for positive controls of immunostaining (Figure 1A). Human tissues were obtained from patients undergoing surgery for the treatment of chronic sinusitis or olfactory neuroblastoma. These included the OM (n = 3), the middle turbinate (n = 5), and inferior turbinate
(n = 6); the latter two were used for the evaluation of the RM. Routine morphology was evaluated in haematoxylin and eosin-stained sections by a qualified pathologist and otolaryngologists. Tissue evaluation was performed only in the parts characterized as non-diseased. All experiments were conducted in accordance with institutional guidelines and with the approval of the Animal Care and Use Committee of the University of Tokyo (No. P14-051, P15-115) and of the Research Ethics Committee of the Graduate School of Medicine and Faculty of Medicine, the University of Tokyo, Japan (12009, 2019073NI). Since archived specimens were used, written informed consent was waived.

Histological analyses

To detect the expressions of ACE2 and TMPRSS2 in the RM, OM, and OB, histological analyses were performed by immunostaining. Four-µm-thick serial paraffin sections were deparaffinized in xylene and dehydrated in ethanol before immunostaining. Prior to immunostaining, deparaffinized sections were treated with 3% hydrogen peroxide to block endogenous peroxidase activity and were incubated in Blocking One (Nacalai Tesque, Kyoto, Japan) to block non-specific immunoglobulin binding. After antigen activation, primary antibodies against ACE2 (1:300 dilution; rabbit monoclonal, Abcam, ab108252; Cambridge, UK),
TMPRSS2 (1:1000 dilution; rabbit monoclonal, Abcam, ab92323; Cambridge, UK), Furin (1:100
dilution; rabbit monoclonal, Abcam, ab183495; Cambridge, UK), and PGP9.5 for a neuronal
marker (1:500 dilution; guinea pig polyclonal, Abcam, ab10410; Cambridge, UK) were detected
with peroxidase conjugated appropriate secondary antibodies and a diaminobenzidine substrate.
The mouse kidney and rat prostate were stained for positive controls for ACE2 and for TMPRSS2
and Furin, respectively (Figure 1B). All samples were stained under the same condition and
protocol as the positive control staining. Images of all sections were captured using a digital
microscope camera (Keyence BZ-X700) with 4×, 10x, 20×, and 40x objective lenses.

Gene expression analyses

Our previous DNA microarray data from the nasal mucosa and OB (NCBI Gene
Expression Omnibus database under the series number GSE 103191, 150694) was used to
examine the expressions of ACE2, TMPRSS2, and Furin. The expression levels of each gene
were normalized against the expression level of Rps3 (encoding ribosomal protein S3) in each
sample.

Results
The immunohistological data is summarized in Table 1. ACE2, TMPRSS2, and Furin were present in human and mouse nasal mucosa and in mouse OB, though the expression pattern of ACE2, TMPRSS2, and Furin varied among tissues. Remarkably, co-expression of ACE2, TMPRSS, and Furin was detected in the supporting cells and Bowman's glands of the OM, and diffusely in the RM, but not in the ORNs of the OM or in the OB.

In mouse RM, ACE2, TMPRSS2, and Furin were all strongly expressed in the cytoplasm of respiratory epithelial cells and in the subepithelial glands (Fig. 1a, b). ACE2 and TMPRSS2 were highly co-expressed in the RE. The villous brush border of the respiratory columnar epithelium was strongly positive for TMPRSS2 expression. In addition, moderate cytoplasmic staining for TMPRSS2 and Furin was observed in the subepithelial tissue (Fig. 2a, b). In OM, only supporting cells and Bowman's glands expressed ACE2, TMPRSS2, and Furin.

The olfactory nerve bundles were moderately positive for ACE2 and TMPRSS2. Notably, all cells in the OE, including supporting cells, ORNs, and basal cells, were positive for ACE2, while the ORNs were negative for TMPRSS2 and Furin (Fig. 2c, d). In the OB, there were no cells expressing ACE2, TMPRSS2, and Furin simultaneously (Fig. 3a-c). ACE2 positive cells were detected in the glomerular layer, mitral cell layer, and granule cell layer, but those cells were negative for TMPRSS2. On the other hand, some cells in the glomerular layer and mitral cells...
were positive for Furin. TMPRSS2 was strongly expressed in cells of the OB core (Fig. 3b).

To reinforce the above histological results, we investigated Ace2, Tmprss2, and Furin gene expression in mouse nasal mucosa and OB. Using the database from the previous study (24), the expression of the three genes was confirmed in the nasal mucosa and OB (Fig. 3d).

In human nasal mucosa, the PGP9.5 antibody clearly visualized the OE containing olfactory neurons. ACE2 was localized in PGP9.5 positive ORNs. In addition, while Furin was not present in the OE, TMPRSS2 was weakly expressed in the apical layer of the OE. (Fig. 4a, b). In the RM, ACE2, TMPRSS2, and Furin were widely co-expressed in the epithelium (Fig. 4c, d). These findings were basically identical to those found in mouse tissues.

Discussion

COVID-19 causes numerous clinical symptoms, including a deteriorated sense of taste and smell, respiratory, and digestive disorders (3, 4, 29). Anosmia, the loss of smell, is a unique clinical feature observed in the early stages of COVID-19. Unlike the anosmia caused in other URIs, the COVID-19 anosmia occurs in most patients and resolves rather quickly. SARS-CoV-2 cell entry is dependent on the expression of the host cell proteins ACE2, TMPRSS2, and Furin.
Since the expression of these proteins in the nasal mucosa remains rather elusive, we investigated the expression of ACE2, TMPRSS2, and Furin in the RM, OM, and OB of human and mouse tissues to elucidate the mechanisms underlying olfactory dysfunction and high viral load in the upper airways of COVID-19 patients. The results of the present study explain why olfaction is frequently impaired in COVID-19 patients. We observed the immunolocalization of ACE2, TMPRSS2, and Furin in the nasal tissue and the OB, which are considered to play a pivotal role in the manifestation of the olfactory dysfunction induced by SARS-CoV-2 infection. Histologically, ACE2, TMPRSS, and Furin were co-expressed in the supporting cells and Bowman’s glands of the OM as well as in the RM, but not in the ORNs of the OM or the OB. Ace2, Tmprss2, and Furin gene expression was confirmed in the nasal mucosa and the OB, supporting the immunohistochemical findings. 

Olfactory dysfunction is defined into three types according to the anatomical location; conductive, sensorineural, and central (30). Conductive dysfunction results from the blockage of odorant airflow to the OE. Sensorineural dysfunction is caused by damage of the ORNs and the olfactory nerve, impaired olfactory adaptation, and/or odorant transport. The supporting cells and the Bowman’s glands are involved in olfactory adaptation and the neurotrophic and physical support of the OE (31-33). Thus, if the function of the supporting cells and the Bowman’s glands
is deteriorated, odor adaptation is impaired, and subsequently, sensorineural dysfunction occurs.

Central dysfunction occurs with the damage of olfactory processing pathways in the central nervous system (30). Based on the present histological results, we suggest that SARS-CoV-2 mainly induces sensorineural olfactory dysfunction without olfactory neuronal damage.

In the olfactory mucosa, co-expression of ACE2, TMPRSS2, and Furin in the supporting cells and the Bowman’s glands suggests that COVID-19 may induce the deterioration of mucus production and OE support, resulting in impaired odor adaptation and transduction. Moreover, co-expression of ACE2 and TMPRSS2 in the olfactory nerve bundle implies that odor transduction may be impaired through neuronal dysfunction. It is unlikely that SARS-CoV-2 directly damages the ORNs in the OM because the ORNs expressed ACE2, but not TMPRSS2 or Furin. Furthermore, the severe damage of ORNs would not explain the early recovery of olfaction observed in COVID-19 patients with anosmia, since the turnover rate of ORNs is approximately 30 days (34). The co-expression of ACE2 and Furin in the mitral cells of the OB, which have large cell bodies and secondary dendrites, suggests that central olfactory dysfunction may occur as a result of synaptic inhibition from the ORNs to the olfactory bulb. Although most COVID-19 patients recover from olfactory dysfunction, some patients have not recovered their olfaction after several months (8). Those COVID-19 patients with prolonged olfactory dysfunction
may have suffered from continuing sensorineural and central olfactory dysfunction.

Considering the high expression of ACE2, TMPRSS2, and Furin in the RE and the subepithelial glands, SARS-CoV-2 possibly induces conductive olfactory dysfunction through hypersecretion and goblet cell hyperplasia (14, 35). In fact, a significant number of COVID-19 patients suffer from nasal obstruction and rhinorrhea (3), but the olfactory symptoms due to conductive olfactory dysfunction may fluctuate and mostly resolve completely. In addition, considering that a certain proportion of COVID-19 patients with hyposmia and anosmia did not exhibit nasal obstruction or rhinitis symptoms (3, 36), the contribution of conductive olfactory loss may be limited. However, some COVID-19 patients with prolonged olfactory dysfunction possibly suffer from continuing sensorineural and central olfactory dysfunction. Future studies are needed for clinical evaluation with long-term-follow-up. As for limitations of the present study, the evaluation was performed on mice and some patients with olfactory neuroblastoma which may not correctly reflect the backgrounds of SARS-CoV-2 infection. Future clinical case studies and autopsy studies might strengthen this study.

In conclusion, the present study demonstrates high expression of ACE2, TMPRSS2, and Furin in the nasal mucosa including the SPs and Bowman’s glands, and in OB. The expression pattern suggests that COVID-19 associated olfactory dysfunction is mainly
sensorineural and central, and to some extent, conductive. The expression of ACE2, but not

TMPRSS2 or Furin, in ORNs may explain the early recovery from anosmia.
References


17. W. Li *et al.*, Angiotensin-converting enzyme 2 is a functional receptor for the SARS


8. 24. R. Ueha *et al.*, Reduction of Proliferating Olfactory Cells and Low Expression of


**Funding:** This work was supported by JSPS KAKENHI Grant-in-Aid for Scientific Research [grant number 24791749, 16K20231] and by the Smoking Research Foundation (Tokyo, Japan).

**Author contributions:** R.U. developed the concept, designed and performed the experiments, and wrote the draft of the manuscript. R.K. and S.S. designed and performed the experiments.
S.U. performed the experiments and wrote partially the draft of the manuscript. K.K, and T.Y. developed the concept, designed the experiments and reviewed the manuscript. All authors contributed to interpretation of the data and writing of the manuscript. **Competing interests:** The authors declare that they have no competing interests. **Data and materials availability:** The datasets generated for this study are available on request to the corresponding author.
Figure 1. Nose sagittal section and representative images of ACE2 staining in mouse kidney, and TMPRSS2 and Furin staining in rat prostate.

a: Sagittal section of the rodent nose. The bars indicate the respiratory mucosal section (RM), olfactory mucosal section (OM), and the olfactory bulb section (OB). b: Positive staining for ACE2 in the kidney, and TMPRSS2 and Furin in the prostate are shown. ACE2 positive cells are observed in the brush border and the cytoplasm and nucleus of tubular cells. TMPRSS2 positive cells are observed in the cytoplasm and nucleus of acinar cells. Furin positive cells are observed in the supranuclear cytoplasm (mainly Golgi apparatus) of acinar cells in the prostate glands.
Figure 2: Representative images of mouse respiratory and olfactory mucosa stained with antibodies against ACE2, TNPRSS2, and Furin.
a and b: The boxes in (a) indicate the parts of the respiratory mucosa (RM) that are shown at higher magnification in (b) (a, 40x magnification; b, 400x magnification). In the RM area, the respiratory epithelium (RE) was stained with ACE2 antibody. On the other hand, TMPRSS2 and Furin were strongly stained in the cilia of the ciliated columnar RE and moderately stained in the supranuclear cytoplasm of RE cells and subepithelial glands. c and d: In the olfactory mucosal (OM) area, supporting cells (SPs, arrows), olfactory receptor neurons (ORNs), and basal cells (BCs, arrow heads) were strongly stained with ACE2 antibody. TMPRSS2 expression was negative in ORNs, moderately positive in SPs, and strongly positive in Bowman’s glands (thick black arrows) and the lamina propria. The olfactory nerve bundles showed weak co-expression of ACE2 and TMPRSS2 (star marks). Furin was also expressed in SPs and Bowman’s glands (thick black arrows) The boxes in (c) indicate the parts of the OM that are shown at higher magnification in (d) (c, 40x magnification; d, 400x magnification).
Figure 3: Representative images of mouse olfactory bulb stained with antibodies against ACE2, TNPRSS2, and Furin; and gene expression levels in the nasal mucosa and olfactory bulb.
The olfactory bulb (OB) area. The boxes in (a) and (b) are shown at higher magnification in (b) and (c), respectively (a, 40x magnification; b, 100x magnification; c, 400x magnification). The OB parenchyma was weakly positive for ACE2, strongly positive for TMPRSS2, and negative for Furin. While ACE2 positive cells could be recognized in the glomerular layer (GL), mitral cell layer (MCL, arrow heads), and granule cell layer (GCL), those cells were negative for TMPRSS2. Some mitral cells were positive for Furin (thick black arrows). TMPRSS2 was strongly expressed in the cells of the OB core (star marks). d: Gene expression levels of Ace2, Tmprss2, and Furin in the nasal mucosa and olfactory bulb are shown relative to the expression of the endogenous control gene Rps3 (encoding ribosomal protein S3). The graph is shown in log_{10} scale.
Figure 4: Representative images of human tissues stained with antibodies against ACE2, TMPRSS2, and Furin.
**a and b:** In the olfactory mucosal area, the area of the olfactory epithelium was recognized using PGP9.5 staining. PGP9.5+ ORNs mostly expressed ACE2, but not TMPRSS2 or Furin. There was high expression of TMPRSS2 in the cytoplasm of the subepithelial glands. Furin was rarely detected in human olfactory epithelium, but a weak expression was noted in the subepithelial glands. The boxes in (a) are shown at higher magnification in (b) (a, 40x magnification; b, 400x magnification). **c - f:** Representative images of the middle turbinate and inferior turbinate. The boxes in (c) and (e) indicate the parts of the respiratory mucosa that are shown at higher magnification in (d) and (f) (c, e, 40x magnification; d, f, 400x magnification). ACE2, TMPRSS2 and Furin protein expression was detected in the respiratory epithelium and subepithelial glands. Specifically, TMPRSS2 expression was well detected.
## Table 1. Protein expression levels of ACE2, TMPRSS2, and Furin in the respiratory mucosa, olfactory mucosa, and olfactory bulb.

<table>
<thead>
<tr>
<th></th>
<th>ACE2</th>
<th>TMPRSS2</th>
<th>Furin</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>RM</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RE</td>
<td>Nucleus</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Cytoplasm</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td><strong>LP</strong></td>
<td>Subepithelial Gland</td>
<td>+</td>
<td>++</td>
</tr>
<tr>
<td><strong>OM</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OE</td>
<td>Supporting cell</td>
<td>++</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>Olfactory receptor neuron</td>
<td>++</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Basal cell</td>
<td>++</td>
<td>±</td>
</tr>
<tr>
<td></td>
<td>Cytoplasm</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td><strong>LP</strong></td>
<td>Bowman's Gland</td>
<td>+</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>Olfactory nerve bundle</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td><strong>OB</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Glomerular layer</td>
<td>++</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Mitral cell layer</td>
<td>++</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Granule cell layer</td>
<td>++</td>
<td>-</td>
</tr>
</tbody>
</table>

**Table 1 legend.**

Both the respiratory mucosa (RM) and olfactory mucosa (OM) can be further subdivided into the epithelium and the lamina propria (LP). In the respiratory epithelium (RE) several cells such as ciliated columnar and globet cells can be found, while the subepithelial glands are found in the LP. The OM, which serves olfaction, consists of an olfactory epithelium (OE), which is composed of olfactory receptor neurons (ORNs) and supporting and basal cells, and the LP, which contains Bowman’s glands and olfactory nerve bundles. Importantly, the degree of olfaction is closely related to the number of mature olfactory receptor neurons (ORNs) in the OE. Moreover, the olfactory system consists of peripheral compartments such as the OM, and central structures such as the olfactory bulb (OB) and the piriform/entorhinal cortex. The olfactory bulb consists of three layers; the glomerular, mitral cell, and granule cell layers.

+: mild expression, ++: moderate to strong expression, -: negative.